References
Key articles
American Diabetes Association. Standards of care in diabetes - 2024. Diabetes Care. 2024 Jan;47(suppl 1):S1-321.Full text
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022 Nov;102(5s):S1-127.Full text Abstract
de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 Dec 1;45(12):3075-90.Full text Abstract
Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.Full text Abstract
Lo C, Toyama T, Wang Y, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018 Sep 24;(9):CD011798.Full text Abstract
Reference articles
1. American Diabetes Association. Standards of care in diabetes - 2024. Diabetes Care. 2024 Jan;47(suppl 1):S1-321.Full text
2. Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016 Aug 9;316(6):602-10.Full text Abstract
3. Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008 May 24;336(7654):1185-9.Full text Abstract
4. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017 May 18;12(12):2032-45.Full text Abstract
5. Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev. 2017 Feb;33(2):dmrr.2841. Abstract
6. Costacou T, Orchard TJ, et al. Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset. Diabetes Care. 2018 Mar;41(3):426-33. Abstract
7. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999 Oct 7;341(15):1127-33. Abstract
8. Kahkoska AR, Isom S, Divers J, et al. The early natural history of albuminuria in young adults with youth-onset type 1 and type 2 diabetes. J Diabetes Complications. 2018 Oct 4;32(12):1160-8. Abstract
9. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 8;392(10159):1789-858.Full text Abstract
10. Perkins BA, Bebu I, de Boer IH, et al. Risk factors for kidney disease in type 1 diabetes. Diabetes Care. 2019 Mar 4;42(5):883-90. Abstract
11. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2015 Nov 7;387(10017):435-43. Abstract
12. Radcliffe NJ, Seah JM, Clarke M, et al. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2016 Jun 8;8(1):6-18.Full text Abstract
13. Sulaiman MK. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr. 2019 Jan 23;11:7.Full text Abstract
14. Li M, Pezzolesi MG. Advances in understanding the genetic basis of diabetic kidney disease. Acta Diabetol. 2018 Aug 6;55(11):1093-104. Abstract
15. Freedman BI, Bostrom M, Daeihagh P, et al. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007 Nov;2(6):1306-16. Abstract
16. Persson F, Rossing P, Hovind P, et al. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scand J Clin Lab Invest. 2008;68(8):731-8. Abstract
17. Shumway JT, Gambert SR. Diabetic nephropathy - pathophysiology and management. Int Urol Nephrol. 2002;34(2):257-64. Abstract
18. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Chapter 1: Definition and classification of CKD. Kidney Int Suppl (2011). 2013 Jan;3(1):19-62.Full text Abstract
19. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-35.Full text Abstract
20. Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023 Dec 12;148(24):1982-2004.Full text Abstract
21. Mohammedi K, Chalmers J, Herrington W, et al. Associations between body mass index and the risk of renal events in patients with type 2 diabetes. Nutr Diabetes. 2018 Jan 17;8(1):7.Full text Abstract
22. O'Brien R, Johnson E, Haneuse S, et al. Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study. Ann Intern Med. 2018 Sep 4;169(5):300-10.Full text Abstract
23. Howden EJ, Coombes JS, Strand H, et al. Exercise training in CKD: efficacy, adherence, and safety. Am J Kidney Dis. 2015 Apr;65(4):583-91. Abstract
24. Leehey DJ, Collins E, Kramer HJ, et al. Structured exercise in obese diabetic patients with chronic kidney disease: a randomized controlled trial. Am J Nephrol. 2016 Jul 7;44(1):54-62. Abstract
25. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 21;157(4):263-75.Full text Abstract
26. Geng Q, Ren J, Song J, et al. Meta-analysis of the effect of statins on renal function. Am J Cardiol. 2014 Aug 15;114(4):562-70. Abstract
27. Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD). Evidence-based European recommendations for the dietary management of diabetes. Diabetologia. 2023 Jun;66(6):965-85.Full text Abstract
28. Jiang S, Fang J, Li W. Protein restriction for diabetic kidney disease. Cochrane Database Syst Rev. 2023 Jan 3;(1):CD014906.Full text Abstract
29. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 Apr 18;42(5):731-54.Full text Abstract
30. Pan Y, Guo LL, Jin HM. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008 Sep;88(3):660-6.Full text Abstract
31. Ruospo M, Saglimbene VM, Palmer SC, et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2017 Jun 8;(6):CD010137.Full text Abstract
32. Gregg EW, Chen H, Bancks MP, et al; Look AHEAD Research Group. Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study. Diabetologia. 2024 Mar;67(3):459-69.Full text Abstract
33. Sattar N, Presslie C, Rutter MK, et al. Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity. Diabetes Care. 2024 Apr 1;47(4):531-43.Full text Abstract
34. Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease. Nat Rev Dis Primers. 2015 Jul 30;1:15018.Full text Abstract
35. Oh SW, Han SY, Han KH, et al; APrODiTe investigators. Morning hypertension and night non-dipping in patients with diabetes and chronic kidney disease. Hypertens Res. 2015 Dec;38(12):889-94.Full text Abstract
36. Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metab. 2020 Apr;22 Suppl 1:3-15.Full text Abstract
37. Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52. Abstract
38. Forrester JV, Kuffova L, Delibegovic M. The role of inflammation in diabetic retinopathy. Front Immunol. 2020 Nov 6;11:583687.Full text Abstract
39. Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019 Jun 13;5(1):41.Full text Abstract
40. Duff M, Demidova O, Blackburn S, et al. Cutaneous manifestations of diabetes mellitus. Clin Diabetes. 2015 Jan;33(1):40-8.Full text Abstract
41. Nitzan O, Elias M, Chazan B, et al. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015 Feb 26:8:129-36.Full text Abstract
42. Shen Y, Li M, Wang K, et al. Diabetic muscular atrophy: molecular mechanisms and promising therapies. Front Endocrinol (Lausanne). 2022 Jun 30;13:917113.Full text Abstract
43. Loutradis C, Skodra A, Georgianos P, et al. Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: a nested case-control study. World J Nephrol. 2016 Jul 6;5(4):358-66.Full text Abstract
44. Sanghavi SF, Swenson ER. Arterial blood gases and acid-base regulation. Semin Respir Crit Care Med. 2023 Oct;44(5):612-26. Abstract
45. Norris KC, Smoyer KE, Rolland C, et al. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. BMC Nephrol. 2018 Feb 9;19(1):36.Full text Abstract
46. Fox CS, Matsushita K, Woodward M, et al; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1662-73.Full text Abstract
47. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022 Nov;102(5s):S1-127.Full text Abstract
48. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 Dec 1;45(12):3075-90.Full text Abstract
49. Johnson DW, Jones GR, Mathew TH, et al; Australasian Proteinuria Consensus Working Group. Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Med J Aust. 2012 Aug 20;197(4):224-5. Abstract
50. Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022 Feb;79(2):268-88.e1.Full text Abstract
51. Lasserson DS, Shine B, O'Callaghan CA, et al. Requirement for cystatin C testing in chronic kidney disease: a retrospective population-based study. Br J Gen Pract. 2017 Oct;67(663):e732-5.Full text Abstract
52. DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021 May;17(5):319-34. Abstract
53. ACR Committee on Drugs and Contrast Media. ACR manual on contrast media. 2022 [internet publication].Full text
54. The Royal College of Radiologists. Guidance on gadolinium-based contrast agent administration to adult patients. Apr 2019 [internet publication].Full text
55. Patney V, Whaley-Connell A, Bakris G. Hypertension management in diabetic kidney disease. Diabetes Spectr. 2015 Aug;28(3):175-80.Full text Abstract
56. Soyoye DO, Abiodun OO, Ikem RT, et al. Diabetes and peripheral artery disease: a review. World J Diabetes. 2021 Jun 15;12(6):827-38.Full text Abstract
57. Valabhji J. Foot problems in patients with diabetes and chronic kidney disease. J Ren Care. 2012 Feb;38 Suppl 1:99-108.Full text Abstract
58. Pop-Busui R, Roberts L, Pennathur S, et al. The management of diabetic neuropathy in CKD. Am J Kidney Dis. 2010 Feb;55(2):365-85.Full text Abstract
59. Li L, Zhang X, Li Z, et al. Renal pathological implications in type 2 diabetes mellitus patients with renal involvement. J Diabetes Complications. 2016 Oct 26;31(1):114-21. Abstract
60. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022 Feb 1;327(5):464-77. Abstract
61. Safian RD, Textor SC. Renal-artery stenosis. N Engl J Med. 2001 Feb 8;344(6):431-42. Abstract
62. Komenda P, Ferguson TW, Macdonald K, et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis. 2014 May;63(5):789-97. Abstract
63. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-54. Abstract
64. Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2023 Oct 1;46(10):e151-99.Full text Abstract
65. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Clin Diabetes. 2016 Apr;34(2):70-80.Full text Abstract
66. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012 Nov;60(5):850-86.Full text Abstract
67. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.Full text Abstract
68. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus: systematic review and meta-analysis of cardiovascular outcomes trials. Circulation. 2019 Apr 23;139(17):2022-31.Full text Abstract
69. Lo C, Toyama T, Wang Y, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018 Sep 24;(9):CD011798.Full text Abstract
70. de Boer IH, Sun W, Cleary PA, et al; DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011 Dec 22;365(25):2366-76.Full text Abstract
71. DCCT/EDIC research group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol. 2014 Oct;2(10):793-800.Full text Abstract
72. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837-53. Abstract
73. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-72.Full text Abstract
74. Ismail-Beigi F, Craven T, Banerji MA, et al; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010 Aug 7;376(9739):419-30. [Erratum in: Lancet. 2010 Oct 30;376(9751):1466.] Abstract
75. Zoungas S, Chalmers J, Neal B, et al; ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014 Oct 9;371(15):1392-406.Full text Abstract
76. Zoungas S, Arima H, Gerstein HC, et al; Collaborators on Trials of Lowering Glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-7. Abstract
77. Agrawal L, Azad N, Bahn GD, et al; VADT Study Group. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2018 Feb;61(2):295-9.Full text Abstract
78. Wong MG, Perkovic V, Chalmers J, et al; ADVANCE-ON Collaborative Group. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care. 2016 May;39(5):694-700.Full text Abstract
79. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59.Full text Abstract
80. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010 Feb 6;375(9713):481-9. Abstract
81. Fullerton B, Jeitler K, Seitz M, et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2014 Feb 14;(2):CD009122.Full text Abstract
82. US Food and Drug Administration. FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Apr 2016 [internet publication].Full text
83. El-Damanawi R, Stanley IK, Staatz C, et al. Metformin for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2024 Jun 4;(6):CD013414.Full text Abstract
84. Augusto GA, Cassola N, Dualib PM, et al. Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus in adults: an overview of 46 systematic reviews. Diabetes Obes Metab. 2021 Oct;23(10):2289-302. Abstract
85. Alicic RZ, Neumiller JJ, Johnson EJ, et al. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes. 2019 Feb;68(2):248-57. Abstract
86. Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017 Jan;28(1):368-75.Full text Abstract
87. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018 Nov 10;393(10166):31-9. Abstract
88. Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J. 2018 Oct 25;11(6):749-61.Full text Abstract
89. Cherney DZI, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-21. Abstract
90. Petrykiv S, Sjöström CD, Greasley PJ, et al. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol. 2017 Mar 16;12(5):751-9.Full text Abstract
91. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644-57.Full text Abstract
92. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct;16(10):1016-27. Abstract
93. Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022 May 10;145(19):1460-70.Full text Abstract
94. Neuen BL, Oshima M, Perkovic V, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. Eur Heart J. 2021 Dec 21;42(48):4891-901.Full text Abstract
95. Qaseem A, Obley AJ, Shamliyan T, et al. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline From the American College of Physicians. Ann Intern Med. 2024 May;177(5):658-66.Full text Abstract
96. Maddaloni E, Cavallari I, La Porta Y, et al. Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023 May;25(5):1341-50.Full text Abstract
97. Butler J, Packer M, Siddiqi TJ, et al. Efficacy of empagliflozin in patients with heart failure across kidney risk categories. J Am Coll Cardiol. 2023 May 16;81(19):1902-14.Full text Abstract
98. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-306.Full text Abstract
99. Sridhar VS, Neuen BL, Fletcher RA, et al. Kidney protection with canagliflozin: a combined analysis of the randomized CANVAS program and CREDENCE trials. Diabetes Obes Metab. 2023 Aug;25(8):2331-9.Full text Abstract
100. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct 8;383(15):1436-46.Full text Abstract
101. Herrington WG, Staplin N, Wanner C, et al; EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 Jan 12;388(2):117-27.Full text Abstract
102. Mosenzon O, Raz I, Wiviott SD, et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care. 2022 Oct 1;45(10):2350-9.Full text Abstract
103. Yau K, Dharia A, Alrowiyti I, et al. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022 Jul;7(7):1463-76.Full text Abstract
104. Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019 Feb 28;18(1):20.Full text Abstract
105. Bhatt DL, Szarek M, Pitt B, et al; SCORED Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021 Jan 14;384(2):129-39.Full text Abstract
106. Bhatt DL, Szarek M, Steg PG, et al; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021 Jan 14;384(2):117-28.Full text Abstract
107. Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021 Sep 15;20(1):189.Full text Abstract
108. Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017 Apr;19(4):524-36. Abstract
109. Mann JFE, Ørsted DD, Brown-Frandsen K, et al; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017 Aug 31;377(9):839-48.Full text Abstract
110. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-85. Abstract
111. Kawai Y, Uneda K, Yamada T, et al. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022 Jan;183:109146. Abstract
112. Ferreira JP, Saraiva F, Sharma A, et al. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials. Diabetes Obes Metab. 2023 Jun;25(6):1495-502. Abstract
113. Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022 Feb 22;145(8):575-85.Full text Abstract
114. Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024 Jul 11;391(2):109-21. Abstract
115. Leehey DJ, Rahman MA, Borys E, et al. Acute kidney injury associated with semaglutide. Kidney Med. 2021 Mar-Apr;3(2):282-5.Full text Abstract
116. Triozzi JL, Parker Gregg L, Virani SS, et al. Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Res Care. 2021 Jul;9(1):e002300.Full text Abstract
117. Simms-Williams N, Treves N, Yin H, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024 Apr 25;385:e078242.Full text Abstract
118. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-55. Abstract
119. Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021 Aug 5;385(6):503-15.Full text Abstract
120. Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-93. Abstract
121. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021 Aug 14;398(10300):583-98. Abstract
122. Del Prato S, Kahn SE, Pavo I, et al; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-24. Abstract
123. Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022 Nov;10(11):774-85. Abstract
124. Mega C, Teixeira-de-Lemos E, Fernandes R, et al. Renoprotective effects of the dipeptidyl peptidase-4 inhibitor sitagliptin: a review in type 2 diabetes. J Diabetes Res. 2017;2017:5164292.Full text Abstract
125. Daza-Arnedo R, Rico-Fontalvo JE, Pájaro-Galvis N, et al. Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: a narrative review. Kidney Med. 2021 Nov-Dec;3(6):1065-73.Full text Abstract
126. Zhou X, Shi H, Zhu S, et al. Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: a meta-analysis. J Diabetes Investig. 2022 Mar;13(3):468-77.Full text Abstract
127. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41(7):471-83. Abstract
128. Sarafidis PA, Stafylas PC, Georgianos PI, et al. Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis. 2010 May;55(5):835-47. Abstract
129. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-62. Abstract
130. Urva S, Quinlan T, Landry J, et al. Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide. Clin Pharmacokinet. 2021 Aug;60(8):1049-59.Full text Abstract
131. Joint British Diabetes Societies for Inpatient Care. Management of adults with diabetes on dialysis. Mar 2023 [internet publication].Full text
132. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013 Aug 6;185(11):949-57.Full text Abstract
133. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):1269-324.Full text Abstract
134. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan - 2022 update. Endocr Pract. 2022 Oct;28(10):923-1049.Full text Abstract
135. Marx N, Federici M, Schütt K, et al; ESC Scientific Document Group. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-140.Full text Abstract
136. National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. Nov 2021 [internet publication].Full text
137. Brouwer TF, Vehmeijer JT, Kalkman DN, et al. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care. 2018 Jun;41(6):1142-8.Full text Abstract
138. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021 Mar;99(3s):S1-87.Full text Abstract
139. Bress AP, King JB, Kreider KE, et al; SPRINT Research Group. Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status: a post hoc analysis of a randomized trial. Diabetes Care. 2017 Aug 9;40(10):1401-8.Full text Abstract
140. Beddhu S, Chertow GM, Greene T, et al. Effects of intensive systolic blood pressure lowering on cardiovascular events and mortality in patients with type 2 diabetes mellitus on standard glycemic control and in those without diabetes mellitus: reconciling results from ACCORD BP and SPRINT. J Am Heart Assoc. 2018 Sep 18;7(18):e009326.Full text Abstract
141. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Nov 2023 [internet publication].Full text
142. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994 Jan 26;271(4):275-9. Abstract
143. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med. 1996 Feb 12;156(3):286-9. Abstract
144. Natale P, Palmer SC, Navaneethan SD, et al. Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 Apr 29;(4):CD006257.Full text Abstract
145. Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59.Full text Abstract
146. Mann JF, Schmieder RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008 Aug 16;372(9638):547-53. Abstract
147. Weil EJ, Fufaa G, Jones LI, et al. Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013 Sep;62(9):3224-31.Full text Abstract
148. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009 Jul 2;361(1):40-51.Full text Abstract
149. Maione A, Navaneethan SD, Graziano G, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011 Sep;26(9):2827-47. Abstract
150. Pham JT, Schmitt BP, Leehey DJ. Effects of dual blockade of the renin angiotensin system in diabetic kidney disease: a systematic review and meta-analysis. J Nephrol Therapeut. 2012;(suppl 2):003.Full text
151. Parving HH, Brenner BM, McMurray JJ, et al; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13.Full text Abstract
152. Fried LF, Emanuele N, Zhang JH, et al; VA NEPHRON-D Investigators. Combined angiotensin inhibition for treatment of diabetic nephropathy. N Engl J Med. 2013 Nov 14;369(20):1892-903.Full text Abstract
153. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012 Aug 1;110(3):383-91. Abstract
154. de Boer IH, Bangalore S, Benetos A, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017 Sep;40(9):1273-84.Full text Abstract
155. Grossman A, Grossman E. Blood pressure control in type 2 diabetic patients. Cardiovasc Diabetol. 2017 Jan 6;16(1):3.Full text Abstract
156. Schroeder EB, Chonchol M, Shetterly SM, et al. Add-on antihypertensive medications to angiotensin-aldosterone system blockers in diabetes: a comparative effectiveness study. Clin J Am Soc Nephrol. 2018 Mar 23;13(5):727-34.Full text Abstract
157. Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021 Dec 30;385(27):2507-19.Full text Abstract
158. Lambers Heerspink HJ, Holtkamp FA, Parving HH, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012 Aug;82(3):330-7.Full text Abstract
159. Levin NW, Kotanko P, Eckardt KU, et al. Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2009 Dec 16;77(4):273-84.Full text Abstract
160. Banerjee D, Winocour P, Chowdhury TA, et al; Association of British Clinical Diabetologists and The Renal Association. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. BMC Nephrol. 2022 Jan 3;23(1):9.Full text Abstract
161. Lee HF, See LC, Chan YH, et al. End-stage renal disease patients using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese nationwide cohort study. Intern Med J. 2018 Sep;48(9):1123-32. Abstract
162. Rossing P, Burgess E, Agarwal R, et al; FIDELIO-DKD Investigators. Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study. Diabetes Care. 2022 Apr 1;45(4):888-97.Full text Abstract
163. Agarwal R, Filippatos G, Pitt B, et al; FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-84.Full text Abstract
164. Yang S, Shen W, Zhang HZ, et al. Efficacy and safety of finerenone for prevention of cardiovascular events in type 2 diabetes mellitus with chronic kidney disease: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2023 Jan 1;81(1):55-62. Abstract
165. McGill JB, Agarwal R, Anker SD, et al; FIDELIO-DKD and FIGARO-DKD investigators. Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab. 2023 Jun;25(6):1512-22.Full text Abstract
166. National Institute for Health and Care Excellence. Finerenone for treating chronic kidney disease in type 2 diabetes. Mar 2023 [internet publication].Full text
167. Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-29.Full text Abstract
168. Filippatos G, Anker SD, Agarwal R, et al; FIGARO-DKD Investigators. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation. 2022 Feb 8;145(6):437-47.Full text Abstract
169. Bansal S, Canziani MEF, Birne R, et al. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19;14(3):e076444.Full text Abstract
170. BMJ Drug Ther Bull. Finerenone for CKD associated with type 2 diabetes. Drug Ther Bull. 2023 Aug;61(8):120-4.Full text Abstract
171. Ding K, Li Z, Lu Y, et al. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease. Eur J Intern Med. 2023 Sep;115:114-27. Abstract
172. Wang H, Zhang GL, Zhang QB, et al. Spironolactone for diabetic nephropathy: a systematic review. Chin J Evid Based Med. 2009;9(1):71-5.
173. Mehdi UF, Adams-Huet B, Raskin P, et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009 Dec;20(12):2641-50.Full text Abstract
174. Epstein M, Williams GH, Weinberger M, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51. Abstract
175. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-72.Full text Abstract
176. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2020 Dec 1;105(12):3613-82.Full text Abstract
177. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019 Jun 18;139(25):e1082-143.Full text Abstract
178. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005 Jul 21;353(3):238-48. Abstract
179. Baigent C, Landray MJ, Reith C, et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25;377(9784):2181-92. Abstract
180. Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023 Mar 14;44(11):972-83.Full text Abstract
181. Arnold SV, Bhatt DL, Barsness GW, et al; American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020 May 12;141(19):e779-806.Full text Abstract
182. Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.Full text Abstract
183. Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012 Nov 13;60(20):2061-71.Full text Abstract
184. Orth SR, Ritz E. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens. 2002 Sep;11(5):483-8. Abstract
185. Academy of Nutrition and Dietetics (American Dietetic Association). 2015 diabetes types 1 and 2 evidence-based nutrition practice guideline. 2015 [internet publication].Full text
186. Sacks FM, Svetkey LP, Vollmer WM, et al; DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001 Jan 4;344(1):3-10.Full text Abstract
187. Hodson EM, Cooper TE. Altered dietary salt intake for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev. 2023 Jan 16;(1):CD006763.Full text Abstract
188. House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010 Apr 28;303(16):1603-9.Full text Abstract
189. Kristensen FPB, Sanchez-Lastra MA, Dalene KE, et al. Leisure-time physical activity and risk of microvascular complications in individuals with type 2 diabetes: a UK Biobank study. Diabetes Care. 2023 Oct 1;46(10):1816-24.Full text Abstract
190. Cai Z, Yang Y, Zhang J. Effects of physical activity on the progression of diabetic nephropathy: a meta-analysis. Biosci Rep. 2021 Jan 29;41(1):BSR20203624.Full text Abstract
191. Gong X, Zeng X, Fu P. The impact of weight loss on renal function in individuals with obesity and type 2 diabetes: a comprehensive review. Front Endocrinol (Lausanne). 2024 Jan 31;15:1320627.Full text Abstract
192. Ollinger R, Margreiter C, Bösmüller C, et al. Evolution of pancreas transplantation: long-term results and perspectives from a high-volume center. Ann Surg. 2012 Nov;256(5):780-6; discussion 786-7. Abstract
193. US Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Mar 2022 [internet publication].Full text
194. US Food and Drug Administration. FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). Jun 2016 [internet publication].Full text
195. Filion KB, Lix LM, Yu OH, et al; Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ. 2020 Sep 23;370:m3342.Full text Abstract
196. McGill JB, Subramanian S. Safety of sodium-glucose co-transporter 2 inhibitors. Am J Cardiol. 2019 Dec 15;124 Suppl 1:S45-52.Full text Abstract
197. Dawwas GK, Flory JH, Hennessy S, et al. Comparative safety of sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis. Diabetes Care. 2022 Apr 1;45(4):919-27.Full text Abstract
198. US Food and Drug Administration. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Sep 2018 [internet publication].Full text
199. UK Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum). Feb 2019 [internet publication].Full text
200. Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021 Jul 17;398(10296):262-76. Abstract
201. UK Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued. Jun 2019 [internet publication].Full text
202. Silverii GA, Monami M, Gallo M, et al. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024 Mar;26(3):891-900.Full text Abstract
203. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010 Apr;151(4):1473-86. Abstract
204. Hu W, Song R, Cheng R, et al. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022 Jul 11;13:927859.Full text Abstract
205. Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023 Feb 1;46(2):384-90.Full text Abstract
206. Thompson CA, Stürmer T. Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care. 2023 Feb 1;46(2):249-51.Full text Abstract
207. US Food and Drug Administration. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. Jan 2024 [internet publication].Full text
208. European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. Jul 2023 [internet publication].Full text
209. Schoretsanitis G, Weiler S, Barbui C, et al. Disproportionality analysis From World Health Organization data on semaglutide, liraglutide, and suicidality. JAMA Netw Open. 2024 Aug 1;7(8):e2423385.Full text Abstract
210. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013 Nov;3(3):259-305.Full text
211. Shan D, Wu HM, Yuan QY, et al. Pentoxifylline for diabetic kidney disease. Cochrane Database Syst Rev. 2012 Feb 15;(2):CD006800.Full text Abstract
212. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015 Jan;26(1):220-9.Full text Abstract
213. Leehey DJ, Carlson K, Reda DJ, et al. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial. BMJ Open. 2021 Aug 16;11(8):e053019.Full text Abstract
214. Shepler B, Nash C, Smith C, et al. Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther. 2012 Jun;34(6):1237-46. Abstract
215. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010 Nov 6;376(9752):1543-51. Abstract
216. Parvanova A, Trillini M, Podestà MA, et al. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. Abstract
217. Vlassara H, Uribarri J, Cai W, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012 Jun;7(6):934-42.Full text Abstract
218. Simpson K, Wonnacott A, Fraser DJ, et al. MicroRNAs in diabetic nephropathy: from biomarkers to therapy. Curr Diab Rep. 2016 Mar;16(3):35.Full text Abstract
219. Huang W, Chen YY, Li ZQ, et al. Recent advances in the emerging therapeutic strategies for diabetic kidney diseases. Int J Mol Sci. 2022 Sep 17;23(18):10882.Full text Abstract
220. ClinicalTrials.gov. A study of GMA301 in subjects with pulmonary arterial hypertension. ClinicalTrials.gov Identifier: NCT04503733. Jan 2022 [internet publication].Full text
221. ClinicalTrials.gov. A study to investigate safe and tolerable dose of GMA301 injection in healthy volunteers. ClinicalTrials.gov Identifier: NCT04505137. Sep 2021 [internet publication].Full text
222. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014 Oct;37(10):2864-83.Full text Abstract
223. Skupien J, Smiles AM, Valo E, et al. Variations in risk of end-stage renal disease and risk of mortality in an international study of patients with type 1 diabetes and advanced nephropathy. Diabetes Care. 2018 Nov 19;42(1):93-101.Full text Abstract
224. Finne P, Groop PH, Arffman M, et al. Cumulative risk of end-stage renal disease among patients with type 2 diabetes: a nationwide inception cohort study. Diabetes Care. 2019 Jan 28;42(4):539-44. Abstract
225. Galindo RJ, Ali MK, Funni SA, et al. Hypoglycemic and hyperglycemic crises among U.S. adults with diabetes and end-stage kidney disease: population-based study, 2013-2017. Diabetes Care. 2022 Jan 1;45(1):100-7.Full text Abstract
226. Fangel MV, Nielsen PB, Kristensen JK, et al. Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease: a Danish cohort study. Am J Med. 2020 Jun;133(6):e269-79. Abstract
227. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med. 1997 Jul 14;157(13):1413-8. Abstract
228. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017 Jul;7(1):1-59.Full text Abstract
229. Pei Y, Hercz G, Greenwood C, et al. Renal osteodystrophy in diabetic patients. Kidney Int. 1993 Jul;44(1):159-64. Abstract
230. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006 Nov 16;355(20):2071-84. Abstract
231. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98. Abstract
232. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) study. Am J Kidney Dis. 2007 Feb;49(2):194-207. Abstract
233. Bakhit M, Fien S, Abukmail E, et al. Cardiovascular disease risk communication and prevention: a meta-analysis. Eur Heart J. 2024 Mar 27;45(12):998-1013.Full text Abstract
234. Lewis EJ, Hunsicker LG, Bain RP, et al; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993 Nov 11;329(20):1456-62.Full text Abstract
235. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9.Full text Abstract
236. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. Jun 2022 [internet publication].Full text
237. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2024 Jan;26(1):5-17.Full text Abstract
238. Mathur M, Jones JR, Weinreb JC. Gadolinium deposition and nephrogenic systemic fibrosis: a radiologist's primer. Radiographics. 2020 Jan-Feb;40(1):153-62.Full text Abstract
239. Lee SW, Kim WJ, Kim YH, et al. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial). Am J Cardiol. 2011 May 15;107(10):1447-52. Abstract
Use of this content is subject to our disclaimer